RxSight Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
RXST$4.90+0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating Activities: | ||
| Net loss | $(48,608) | $(66,756) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 4,078 | 3,884 |
| Amortization of right-of-use lease assets | 165 | 138 |
| Amortization of debt issuance costs and premium | 287 | 552 |
| Loss on extinguishment of debt | 1,769 | — |
| Amortization of discount on short-term investments | (6,122) | (1,405) |
| Stock-based compensation | 15,746 | 11,397 |
| Provision for excess and obsolete inventory | 164 | 752 |
| Change in operating assets and liabilities: | ||
| Accounts receivable | (9,325) | (6,094) |
| Inventories | (2,749) | (7,555) |
| Prepaid and other assets | (562) | 789 |
| Accounts payable | 1,250 | 635 |
| Accrued expenses and other liabilities | 2,314 | 4,813 |
| Net cash used in operating activities | (41,593) | (58,850) |
| Investing Activities: | ||
| Purchase of property and equipment | (4,814) | (2,393) |
| Maturity of short-term investments | 255,000 | 255,000 |
| Purchases of short-term investments | (272,315) | (212,657) |
| Net cash (used in) provided by investing activities | (22,129) | 39,950 |
| Financing Activities: | ||
| Proceeds from term loan | 20,000 | — |
| Repayment of term loan | (60,000) | — |
| Proceeds from issuance of common stock from public offering | 54,050 | — |
| Proceeds from issuance of common stock for at-the-market offerings | 42,434 | 6,050 |
| Proceeds from issuance of common stock | 9,473 | 1,778 |
| Payments for employee taxes related to stock compensation | (1,423) | (643) |
| Principal payments on finance lease liabilities | (153) | (121) |
| Payments of deferred offering costs | (622) | (587) |
| Payments of debt issuance costs | (2,235) | (145) |
| Net cash provided by financing activities | 61,524 | 6,332 |
| Effect of foreign exchange rate on cash, cash equivalents and restricted cash | 6 | (9) |
| Net decrease in cash, cash equivalents and restricted cash | (2,192) | (12,577) |
| Cash, cash equivalents and restricted cash - beginning of period | 12,595 | 25,172 |
| Cash, cash equivalents and restricted cash - end of period | $10,403 | $12,595 |
| Supplemental disclosure of cash flow information: | ||
| Operating cash flows from operating leases | 2,216 | 2,187 |
| Cash paid for income taxes | 8 | 3 |
| Cash paid for interest on financing leases | 12 | 18 |
| Cash paid for interest on term loan | 3,464 | 4,239 |
| Non-cash investing and financing activities: | ||
| Right-of-use assets obtained in exchange for lease obligations: | ||
| Operating lease | 46 | 1,090 |
| Finance lease | 102 | 311 |
| Lease obligations recorded for right-of-use assets: | ||
| Operating lease | 46 | 1,090 |
| Finance lease | 102 | 311 |
| Acquisition of property and equipment included in accounts payable and accrued expenses and other current liabilities | 282 | 299 |
| Deferred offering costs included in accounts payable and accrued liabilities | 145 | 133 |
| Reclassification of deferred financing costs | 1,390 | 90 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.